Institutional investors purchased a net $421.4 thousand shares of NVIV during the quarter ended September 2017 and now own 11.56% of the total shares outstanding. This is a greater percentage than is typical for companies in the Biotechnology industry and highlights that the smart money sees this stock as an important holding.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
IMS CAPITAL MANAGEMENT, INC. Bought 128.9 Thousand shares of InVivo Therapeutics Holdi...